Palexia (Tapentadol): Uses, Dosage & Side Effects
Strong opioid analgesic for moderate to severe acute pain in adults
Palexia contains the active substance tapentadol, a strong opioid analgesic with a unique dual mechanism of action. It is prescribed for the relief of moderate to severe acute pain in adults when non-opioid painkillers are insufficient. This comprehensive guide covers uses, correct dosage, potential side effects, drug interactions, and important safety information based on international clinical guidelines.
Quick Facts: Palexia
Key Takeaways
- Palexia (tapentadol) is a strong opioid used for moderate to severe acute pain in adults when other painkillers are not effective enough.
- It has a unique dual mechanism of action (MOR-NRI) — mu-opioid receptor agonism combined with noradrenaline reuptake inhibition — which may offer better gastrointestinal tolerability compared to classic opioids.
- Palexia carries serious risks including respiratory depression, dependence, and addiction. It should only be taken exactly as prescribed by your doctor.
- Never combine Palexia with alcohol, benzodiazepines, MAO inhibitors, or other central nervous system depressants, as this can be life-threatening.
- Do not stop taking Palexia suddenly — gradual dose reduction under medical supervision is recommended to prevent withdrawal symptoms.
What Is Palexia and What Is It Used For?
Quick Answer: Palexia (tapentadol) is a strong opioid analgesic prescribed for the relief of moderate to severe acute pain in adults. It is used when non-opioid painkillers alone cannot adequately control pain. Tapentadol works through a dual mechanism combining mu-opioid receptor agonism with noradrenaline reuptake inhibition.
Tapentadol, the active substance in Palexia, belongs to the class of centrally acting strong opioid analgesics. It was developed by Grünenthal GmbH and approved by the European Medicines Agency (EMA) for the management of acute pain in adults. Unlike traditional opioids such as morphine or oxycodone that act primarily through mu-opioid receptor agonism alone, tapentadol employs a dual mechanism of action known as MOR-NRI (mu-opioid receptor agonist – noradrenaline reuptake inhibitor).
This dual mechanism means that tapentadol provides pain relief through two complementary pharmacological pathways. The mu-opioid receptor agonism modulates pain signals in the central nervous system, similar to other opioids. Simultaneously, the noradrenaline reuptake inhibition enhances descending inhibitory pain pathways in the spinal cord. Clinical research published in Current Medical Research and Opinion (2012) has demonstrated that this synergistic approach can deliver effective analgesia with a potentially more favourable gastrointestinal tolerability profile compared to equianalgesic doses of classical mu-opioid agonists.
Palexia is specifically indicated for the relief of moderate to severe acute pain in adults that can only be adequately managed with opioid analgesics. It is typically prescribed for short-term use following surgical procedures, traumatic injuries, or other conditions causing significant acute pain. The immediate-release formulation allows for flexible dosing, with pain relief typically beginning within 30 minutes of oral administration and peak plasma concentrations reached within approximately 1.25 hours.
It is important to understand that Palexia is not appropriate for mild pain or chronic pain management in its immediate-release form. For chronic pain requiring around-the-clock opioid treatment, prolonged-release formulations of tapentadol (marketed under different brand names) may be considered by your physician. Always follow your prescriber's instructions regarding the use of this medication, and discuss any concerns about pain management with your healthcare provider.
What Should You Know Before Taking Palexia?
Quick Answer: Palexia must not be used by people with severe breathing problems, paralytic ileus, acute alcohol or drug intoxication, or those taking MAO inhibitors. Special caution is needed if you have liver or kidney disease, a history of seizures, or a history of substance abuse. Palexia carries risks of dependence and should be used exactly as prescribed.
Contraindications
There are several situations in which Palexia must not be taken. Your doctor will assess whether any of these apply to you before prescribing this medication. Do not take Palexia if you:
- Are allergic to tapentadol or any of the other ingredients in the tablet (including lactose monohydrate, croscarmellose sodium, povidone K30, magnesium stearate, polyvinyl alcohol, titanium dioxide E 171, macrogol 3350, and talc).
- Have asthma or dangerously slow or shallow breathing (respiratory depression with elevated carbon dioxide levels).
- Have paralysis of the bowel (paralytic ileus).
- Are acutely intoxicated with alcohol, sleeping pills, opioid painkillers, or other psychotropic substances that affect mood and emotions.
- Are currently taking or have taken MAO inhibitors (a type of antidepressant) within the last 14 days.
Warnings and Precautions
Talk to your doctor or pharmacist before taking Palexia if any of the following conditions apply to you. These situations require special caution and your doctor may need to adjust your dose or monitoring:
- Breathing difficulties: If you have slow or shallow breathing, Palexia can further suppress respiratory function, potentially leading to life-threatening respiratory depression. This risk is highest during the first 24–72 hours of treatment or after a dose increase.
- Increased intracranial pressure or head injury: Tapentadol can elevate intracranial pressure and may mask neurological signs. If you have a head injury, brain tumour, or reduced level of consciousness, extra caution is required.
- Liver or kidney disease: Patients with moderate liver impairment may need a different dosing interval. Those with severe liver or kidney problems should not take Palexia. No dose adjustment is necessary for mild liver or kidney impairment.
- Pancreatic or biliary tract disease: Tapentadol may cause spasm of the sphincter of Oddi, which can worsen conditions affecting the pancreas or bile ducts, including pancreatitis.
- Seizure disorder: If you have a tendency to develop seizures or epilepsy, or if you take medications that can lower the seizure threshold, the risk of seizures may be increased with Palexia.
- Use of mixed opioid agonists/antagonists: Taking medications such as pentazocine, nalbuphine, or partial mu-opioid agonists such as buprenorphine may reduce the effectiveness of Palexia.
Palexia contains tapentadol, an opioid medication. Repeated use can lead to tolerance (needing higher doses for the same effect), physical dependence, and addiction, with a risk of life-threatening overdose. The risk increases with higher doses and longer duration of use. You may be at greater risk if you or a family member have a history of substance abuse, if you smoke, or if you have a history of mental health conditions such as depression, anxiety, or personality disorders. If you notice that you need the medication for longer than prescribed, need higher doses, feel compelled to continue using it despite no pain relief, or use it for reasons other than prescribed — speak to your doctor immediately.
Palexia can cause sleep-related breathing disorders such as central sleep apnoea and sleep-related hypoxaemia (low blood oxygen during sleep). Symptoms may include breathing pauses during sleep, night-time awakenings due to breathlessness, difficulty maintaining sleep, or excessive daytime drowsiness. If you or someone else notices these symptoms, contact your doctor, who may consider reducing your dose.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking Palexia. This medication poses specific risks during pregnancy and breastfeeding:
- Pregnancy: Do not take Palexia during pregnancy unless your doctor has specifically instructed you to do so. Prolonged use of tapentadol during pregnancy can lead to neonatal withdrawal syndrome (neonatal abstinence syndrome) in the newborn, which can be life-threatening if not recognised and treated by a physician. Symptoms in the newborn may include irritability, hyperactivity, abnormal sleep pattern, high-pitched crying, tremor, vomiting, diarrhoea, and failure to gain weight.
- Labour and delivery: Palexia should not be used during childbirth as it may cause dangerously slow or shallow breathing (respiratory depression) in the newborn.
- Breastfeeding: Do not take Palexia while breastfeeding, as tapentadol may be excreted in breast milk and could affect the nursing infant.
Driving and Operating Machinery
Palexia can cause drowsiness, dizziness, and blurred vision, and may impair your ability to react. These effects are particularly likely when you first start treatment, when your doctor changes your dose, or when you consume alcohol or take sedative medications. Do not drive or operate machinery until you know how Palexia affects you. You are personally responsible for assessing whether you are fit to drive or perform work that requires alertness.
How Does Palexia Interact with Other Drugs?
Quick Answer: Palexia can interact dangerously with many medications. The most critical interactions are with MAO inhibitors (contraindicated), benzodiazepines and other CNS depressants (risk of respiratory depression and death), serotonergic drugs (risk of serotonin syndrome), and gabapentin/pregabalin (increased overdose risk). Always tell your doctor about all medications you take.
Drug interactions with Palexia can be serious and even life-threatening. Because tapentadol acts on the central nervous system through multiple pathways, it has the potential to interact with a wide range of medications. The following table summarises the most important interactions. Always inform your doctor, pharmacist, or other healthcare professional about all medications you are currently taking, have recently taken, or might take.
Major Interactions
| Drug / Drug Class | Interaction Risk | Clinical Effect |
|---|---|---|
| MAO inhibitors (e.g. phenelzine, tranylcypromine, moclobemide) | Contraindicated | Potentially fatal reactions including serotonin syndrome, hypertensive crisis, and cardiovascular collapse. Do not take within 14 days of MAO inhibitor use. |
| Benzodiazepines (e.g. diazepam, lorazepam, alprazolam) | Severe | Increased risk of profound sedation, respiratory depression, coma, and death. Concurrent use should only be considered when no alternative treatment options exist. |
| Other opioid analgesics (e.g. morphine, codeine, tramadol) | Severe | Additive respiratory depression, sedation, and increased overdose risk. |
| Gabapentin and pregabalin | Severe | Increased risk of opioid overdose, respiratory depression, and death. Dose should be carefully limited. |
| Serotonergic drugs (SSRIs, SNRIs, tricyclic antidepressants, triptans) | Severe | Risk of serotonin syndrome: involuntary muscle contractions, agitation, excessive sweating, tremor, hyperreflexia, hyperthermia above 38°C. Can be life-threatening. |
| Alcohol | Severe | Increased sedation, respiratory depression, and risk of fatal overdose. Do not consume any alcohol while taking Palexia. |
Moderate Interactions
| Drug / Drug Class | Interaction Risk | Clinical Effect |
|---|---|---|
| Barbiturates (e.g. phenobarbital) | Moderate–Severe | Enhanced CNS depression, sedation, and respiratory depression. Phenobarbital is also a CYP enzyme inducer that may alter tapentadol metabolism. |
| Mixed agonists/antagonists (pentazocine, nalbuphine) and partial agonists (buprenorphine) | Moderate | May reduce the analgesic effect of Palexia. Concurrent use has not been studied and should be avoided. |
| CYP enzyme inducers (rifampicin, St. John’s Wort) | Moderate | May reduce the effectiveness of tapentadol or cause unexpected side effects, particularly when the inducing treatment is started or stopped. |
| Anticholinergic drugs (certain antidepressants, antihistamines, antipsychotics, muscle relaxants, anti-Parkinson drugs) | Moderate | Increased risk of anticholinergic side effects such as constipation, urinary retention, dry mouth, and confusion. |
| Antipsychotics and sedating antihistamines | Moderate | Enhanced sedation, drowsiness, and impaired cognitive function. |
This list does not include all possible interactions. Always tell your doctor and pharmacist about every medication you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements. It may also be helpful to inform friends and family members about the warning signs of respiratory depression and excessive sedation so they can seek help on your behalf if necessary.
What Is the Correct Dosage of Palexia?
Quick Answer: The usual starting dose for adults is 50 mg every 4 to 6 hours as needed. The maximum dose is 700 mg on the first day and 600 mg on subsequent days. Dose adjustments are needed for patients with moderate liver impairment. Palexia is not suitable for children under 18 years.
Always take Palexia exactly as your doctor or pharmacist has told you. Before starting treatment and at regular intervals during treatment, your doctor will discuss what to expect from using Palexia, how long you should take it, when to contact your doctor, and when to stop treatment. As a general rule, the lowest effective dose for pain relief should be used.
Adults
Standard Adult Dosing
The usual starting dose is 50 mg tapentadol every 4 to 6 hours. Your doctor may prescribe a different dose or dosing interval based on your individual pain intensity and response. Swallow the tablets whole with an adequate amount of liquid. You may take Palexia with or without food.
- First day of treatment: Total daily doses higher than 700 mg are not recommended.
- Subsequent days: Total daily doses higher than 600 mg are not recommended.
If you feel the effect is too strong or too weak, talk to your doctor or pharmacist.
Elderly Patients
Patients Over 65 Years
No dose adjustment is usually necessary for elderly patients. However, elimination of tapentadol may be delayed in some older individuals. If this applies to you, your doctor may recommend a different dosing interval with longer periods between doses.
Liver and Kidney Impairment
Hepatic and Renal Dose Adjustments
- Severe liver problems: Palexia should not be used.
- Moderate liver problems: Your doctor will recommend a different dosing interval.
- Mild liver problems: No dose adjustment required.
- Severe kidney problems: Palexia should not be used.
- Mild to moderate kidney problems: No dose adjustment required.
Children and Adolescents
Under 18 Years
Palexia is not suitable for children and adolescents under 18 years of age. The safety and efficacy of tapentadol have not been established in this age group.
Missed Dose
If you forget to take a dose of Palexia, you will likely notice the pain returning. Do not take a double dose to make up for the missed one. Simply take the next dose at the usual time and continue as before.
Overdose
If you or someone else has taken too much Palexia, or if a child has accidentally ingested the medication, contact emergency services or a poison control centre immediately. An overdose of tapentadol can be fatal.
Symptoms of overdose may include:
- Pinpoint pupils (miosis)
- Vomiting
- Drop in blood pressure (hypotension)
- Rapid heartbeat (tachycardia)
- Reduced consciousness or coma
- Seizures
- Dangerously slow or shallow breathing, or complete cessation of breathing — which can be fatal
Stopping Treatment
Do not stop taking Palexia suddenly without consulting your doctor, even if you feel better. Abrupt discontinuation after prolonged use may cause withdrawal symptoms. Although most patients can stop without problems, some individuals who have taken the medication for an extended period may experience the following symptoms:
- Restlessness, watery eyes, runny nose, yawning, sweating, chills, muscle pain, and dilated pupils
- Irritability, anxiety, back pain, joint pain, weakness, abdominal cramps, difficulty sleeping, nausea, loss of appetite, vomiting, diarrhoea, increased blood pressure, increased breathing rate, or increased heart rate
If you experience any of these symptoms after stopping treatment, consult your doctor. Your doctor may recommend a gradual dose reduction to minimise or prevent withdrawal effects.
What Are the Side Effects of Palexia?
Quick Answer: The most common side effects of Palexia are nausea, vomiting, dizziness, drowsiness, and headache (affecting more than 1 in 10 people). Serious but less common side effects include respiratory depression, allergic reactions, seizures, and serotonin syndrome. If you experience difficulty breathing, facial swelling, or severe allergic symptoms, seek medical attention immediately.
Like all medicines, Palexia can cause side effects, although not everybody gets them. The following section lists side effects by how often they occur. Understanding these frequencies helps you put your individual risk into perspective, but remember that many people take tapentadol without experiencing significant problems.
- Allergic reactions: wheezing, difficulty breathing, swelling of eyelids, face or lips, rash or itching (especially if it covers the whole body)
- Breathing that is slower or weaker than expected — this is particularly dangerous in elderly and frail patients
Very Common
May affect more than 1 in 10 people
- Nausea
- Vomiting
- Dizziness
- Drowsiness (somnolence)
- Headache
Common
May affect up to 1 in 10 people
- Decreased appetite
- Anxiety, confusion, hallucinations
- Sleep problems (insomnia), abnormal dreams
- Tremor
- Flushing
- Constipation, diarrhoea, indigestion (dyspepsia), dry mouth
- Itching (pruritus), increased sweating (hyperhidrosis), rash
- Muscle spasms
- Feeling of weakness (asthenia), fatigue
- Feeling of change in body temperature
Uncommon
May affect up to 1 in 100 people
- Depressed mood, disorientation, agitation, nervousness, restlessness, euphoria
- Drug dependence, attention disturbances, memory impairment
- Pre-syncope (feeling faint), sedation, difficulty controlling movements, speech difficulties
- Numbness, tingling, abnormal skin sensations (paraesthesia), muscle twitching
- Visual disturbances
- Increased heart rate, palpitations, decreased blood pressure
- Respiratory depression, decreased blood oxygen, shortness of breath
- Abdominal discomfort, urticaria (hives)
- Delayed bladder emptying, frequent urination
- Drug withdrawal symptoms, oedema (swelling)
- Feeling abnormal, feeling of intoxication, irritability, feeling of relaxation
Rare
May affect up to 1 in 1,000 people
- Severe allergic reactions (angioedema, urticaria, and in serious cases: breathing difficulties, blood pressure drop, collapse, or shock)
- Abnormal thinking, seizures (epileptic fits)
- Reduced level of consciousness
- Impaired coordination (ataxia)
- Decreased heart rate (bradycardia)
- Delayed gastric emptying
Frequency Not Known
Cannot be estimated from available data
- Delirium
Generally, patients suffering from chronic pain are at greater risk of suicidal thoughts and suicidal behaviour. Additionally, certain medicines used to treat depression (which affect neurotransmitters in the brain) may increase this risk, particularly at the beginning of treatment. Although tapentadol also affects neurotransmitters, data from human use of tapentadol have not provided evidence of an increased risk. If you experience thoughts of self-harm or suicide, contact your doctor or a mental health professional immediately.
If you experience any side effects, including any not listed above, talk to your doctor or pharmacist. You can also report side effects directly to your national pharmacovigilance authority, which helps ensure continuous monitoring of the medicine's benefit–risk balance.
How Should You Store Palexia?
Quick Answer: Store Palexia out of the sight and reach of children and in a secure place where others cannot access it. No special storage conditions are required. Do not use after the expiry date printed on the carton and blister pack. Dispose of unused medication through your pharmacy — do not discard in household waste or down the drain.
Because Palexia is a strong opioid, proper storage is critically important to prevent accidental ingestion or misuse. Store this medicine in a secure location where other people, especially children, cannot access it. Accidental ingestion of tapentadol can cause serious harm and may be fatal, particularly for individuals who have not been prescribed the medication.
- Keep out of sight and reach of children at all times.
- Store securely to prevent access by others — opioid misuse can cause serious harm or death.
- No special storage requirements: No specific temperature or humidity conditions are necessary.
- Expiry date: Do not use after the expiry date stated on the carton (after "EXP") and on the blister pack. The expiry date refers to the last day of that month.
- Disposal: Return unused or expired medication to your pharmacy for safe disposal. Do not throw medicines in household waste or flush them down the drain, as this protects the environment.
What Does Palexia Contain?
Quick Answer: Each Palexia 50 mg film-coated tablet contains 50 mg tapentadol (as 58.24 mg tapentadol hydrochloride) as the active ingredient. The tablet is a white, round, 7 mm film-coated tablet marked with the Grünenthal logo on one side and "H6" on the other.
Active Ingredient
Each film-coated tablet contains 50 mg tapentadol (equivalent to 58.24 mg tapentadol hydrochloride).
Inactive Ingredients (Excipients)
The other ingredients serve various pharmaceutical functions in the tablet:
- Tablet core: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, povidone K30, magnesium stearate
- Film coating: polyvinyl alcohol, titanium dioxide (E 171), macrogol 3350, talc
This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. Palexia contains less than 1 mmol (23 mg) sodium per tablet, meaning it is essentially sodium-free.
Appearance and Pack Sizes
Palexia 50 mg tablets are white, round, film-coated tablets measuring 7 mm in diameter, marked with the Grünenthal logo on one side and "H6" on the other. They are packaged in blister packs and available in cartons of 5, 10, 14, 20, 24, 28, 30, 40, 50, 54, 56, 60, 90, or 100 tablets (some with unit-dose blisters). Not all pack sizes may be marketed in your country.
Marketing Authorisation Holder and Manufacturer
Grünenthal GmbH, Zieglerstrasse 6, 52078 Aachen, Germany.
Frequently Asked Questions About Palexia
Palexia (tapentadol) is a strong opioid analgesic used for the relief of moderate to severe acute pain in adults. It is prescribed when non-opioid painkillers cannot adequately manage the pain. Common situations include post-surgical pain, pain from traumatic injuries, and other conditions causing significant acute pain. Palexia works through a unique dual mechanism combining mu-opioid receptor agonism with noradrenaline reuptake inhibition (MOR-NRI).
Yes, Palexia carries a risk of addiction as it contains tapentadol, an opioid substance. Repeated use can lead to tolerance (needing higher doses for the same effect), physical dependence, and psychological addiction. Risk factors include a personal or family history of substance abuse, smoking, and a history of mental health conditions. To minimise this risk, always take Palexia exactly as prescribed, use the lowest effective dose, and do not extend treatment beyond what your doctor recommends.
The most common side effects, affecting more than 1 in 10 people, are nausea, vomiting, dizziness, drowsiness, and headache. Common side effects (up to 1 in 10) include decreased appetite, anxiety, confusion, hallucinations, sleep problems, tremor, constipation, diarrhoea, dry mouth, itching, increased sweating, rash, muscle spasms, weakness, and fatigue. Most side effects are dose-dependent and may improve as your body adjusts to the medication.
No, you must not drink alcohol while taking Palexia. Combining tapentadol with alcohol significantly increases the risk of drowsiness, respiratory depression (dangerously slow breathing), coma, and death. Even small amounts of alcohol can amplify these effects. This interaction is one of the most dangerous associated with opioid medications.
Palexia should not be used during pregnancy unless your doctor specifically advises it. Prolonged use during pregnancy can cause neonatal withdrawal syndrome (neonatal abstinence syndrome) in the newborn, which can be life-threatening if not recognised and treated. Palexia should not be used during labour as it may cause respiratory depression in the newborn. It is also not recommended while breastfeeding, as tapentadol may pass into breast milk.
An overdose of Palexia is a medical emergency and can be fatal. Symptoms include pinpoint pupils, vomiting, low blood pressure, rapid heartbeat, reduced consciousness or coma, seizures, and dangerously slow or stopped breathing. If you suspect an overdose, call emergency services immediately or go to the nearest emergency department. Do not wait for symptoms to worsen. If available, naloxone (an opioid antagonist) can temporarily reverse the effects while awaiting emergency medical care.
References
This article is based on the following international medical guidelines and peer-reviewed sources:
- European Medicines Agency (EMA). Palexia Summary of Product Characteristics (SmPC). Available at: www.ema.europa.eu.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
- WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: WHO; 2018.
- Tzschentke TM, et al. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today. 2009;45(7):483–496.
- Hartrick CT, Rozek RJ. Tapentadol in pain management: a mu-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs. 2011;25(5):359–370.
- Langford RM, et al. Efficacy of tapentadol immediate release for acute post-operative pain. Current Medical Research and Opinion. 2012;28(10):1617–1634.
- National Institute for Health and Care Excellence (NICE). Opioids for pain relief: information for adults. NICE Clinical Knowledge Summaries. 2023.
- British National Formulary (BNF). Tapentadol Monograph. Available at: bnf.nice.org.uk.
- U.S. Food and Drug Administration (FDA). Tapentadol Prescribing Information. Available at: www.fda.gov.
- Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022. MMWR Recomm Rep. 2022;71(No. RR-3):1–95.
Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, which includes board-certified physicians specialising in clinical pharmacology, pain medicine, and internal medicine. Our content follows the GRADE evidence framework and adheres to international guidelines from the WHO, EMA, FDA, and NICE.
Evidence Standard
Level 1A – Based on systematic reviews, meta-analyses, and international treatment guidelines from WHO, EMA, FDA, and BNF.
Editorial Independence
No pharmaceutical company sponsorship or advertising. All content is independent and free from commercial influence.